HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation.

Abstract
The efficacy of hematopoietic stem cell transplantation (HSCT) for Hunter disease (deficiency of iduronate-2-sulfatase, IDS) remains unclear. We treated a 6-year-old male suffering from a severe type of Hunter disease with cord blood stem cell transplantation (CBSCT); however, he died at 10 months post-therapy due to a laryngeal post-transplantation lymphoproliferative disorder. During the follow-up period after CBSCT, his hyperactivity, estimated mental age, and brain MR findings had not improved. We assessed the efficacy of CBSCT by biochemical and pathological analyses of the autopsied tissues. There were many distended cells with accumulated substrate in the brain, but not in the liver. IDS enzyme activity in the cerebrum remained very low, although that in the liver reached about 40% of the normal control level. However, a variable number of tandem repeats analyses demonstrated a weak donor-derived band not only in the liver but also in the cerebrum. Furthermore, IDS-immunoreactivity in the liver was recognized broadly not only in Kupffer cells but also in hepatocytes. On the other hand, IDS-immunoreactivity was recognized exclusively in CD68-positive microglia/monocytes in the patient's brain; whereas that in the normal brain was also detected in neurons and oligodendrocytes. These donor-derived IDS-positive cells were predominantly localized in perivascular spaces and some of them were evidently present in the brain parenchyma. The efficacy of CBSCT was judged to be insufficient for the brain at 10 months post-therapy. However, the pathological detection of donor-derived cells in the brain parenchyma suggests the potential of HSCT for treatment of neurological symptoms in Hunter disease. This is the first neuropathological report documenting the distribution of donor-derived cells in the brain after CBSCT into a Hunter disease patient.
AuthorsKen Araya, Norio Sakai, Ikuko Mohri, Kuriko Kagitani-Shimono, Takeshi Okinaga, Yoshiko Hashii, Hideaki Ohta, Itsuko Nakamichi, Katsuyuki Aozasa, Masako Taniike, Keiichi Ozono
JournalMolecular genetics and metabolism (Mol Genet Metab) Vol. 98 Issue 3 Pg. 255-63 (Nov 2009) ISSN: 1096-7206 [Electronic] United States
PMID19556155 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Brain (metabolism, pathology)
  • Child
  • Cord Blood Stem Cell Transplantation
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Mucopolysaccharidosis II (pathology, therapy)
  • Tissue Donors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: